Figure 9
From: Multiplexed Autoantibody Signature for Serological Detection of Canine Mammary Tumours
Diagnostic value of different autoantibody biomarker panels for canine mammary tumour: (A) With successive addition of TAAs to a total of 5 antigens in the multiplex assay, there is a stepwise increase in sensitivity. Out of 75 CMT sera samples analysed, 78.67% showed detectable level of autoantibodies cumulatively to any of these five TAAs, which was significantly higher than the frequency in sera from healthy individuals(n = 50) (p < 0.001). (B) Comparison of ROC curves reveals that with increase in the number of biomarkers in the panel, there is also an increase in AUC, with maximum AUC of 0.931(p < 0.0001) for the combined panel of five biomarkers.
